WO2018088826A3 - 대장암 전이 진단 또는 예후 예측용 조성물 및 이의 용도 - Google Patents

대장암 전이 진단 또는 예후 예측용 조성물 및 이의 용도 Download PDF

Info

Publication number
WO2018088826A3
WO2018088826A3 PCT/KR2017/012691 KR2017012691W WO2018088826A3 WO 2018088826 A3 WO2018088826 A3 WO 2018088826A3 KR 2017012691 W KR2017012691 W KR 2017012691W WO 2018088826 A3 WO2018088826 A3 WO 2018088826A3
Authority
WO
WIPO (PCT)
Prior art keywords
colorectal cancer
cancer metastasis
composition
predicting prognosis
diagnosing colorectal
Prior art date
Application number
PCT/KR2017/012691
Other languages
English (en)
French (fr)
Other versions
WO2018088826A2 (ko
Inventor
김남순
전수영
조현수
이정주
이용재
민주식
안준호
윤지용
전수진
정초록
최민혁
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2018088826A2 publication Critical patent/WO2018088826A2/ko
Publication of WO2018088826A3 publication Critical patent/WO2018088826A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G01N2333/90248—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13
    • G01N2333/90251—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one of the donors, and incorporation of one atom of oxygen 1.14.13 with a definite EC number (1.14.13.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명에서는 스쿠알렌 에폭시다제(squalene epoxidase) 및/또는 p53 유전자의 mRNA 또는 이의 단백질의 수준을 측정하는 제제를 포함하는 대장암 전이 진단용 조성물을 이용하여, 대장암 전이를 진단 및/또는 대장암의 예후를 예측할 수 있다.
PCT/KR2017/012691 2016-11-09 2017-11-09 대장암 전이 진단 또는 예후 예측용 조성물 및 이의 용도 WO2018088826A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0148930 2016-11-09
KR20160148930 2016-11-09

Publications (2)

Publication Number Publication Date
WO2018088826A2 WO2018088826A2 (ko) 2018-05-17
WO2018088826A3 true WO2018088826A3 (ko) 2018-08-09

Family

ID=62109224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012691 WO2018088826A2 (ko) 2016-11-09 2017-11-09 대장암 전이 진단 또는 예후 예측용 조성물 및 이의 용도

Country Status (2)

Country Link
KR (1) KR102006999B1 (ko)
WO (1) WO2018088826A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210150221A (ko) 2020-06-03 2021-12-10 한국생명공학연구원 암 전이 및 재발 진단용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260177A1 (en) 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
KR100969692B1 (ko) * 2008-01-18 2010-07-14 한국생명공학연구원 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR100973990B1 (ko) * 2008-04-02 2010-08-05 한국생명공학연구원 대장암 진단용 마커 ｐｒｒ7과 이에 의해 코드되는 단백질 및 이를 이용한 대장암 진단 키트
KR101007574B1 (ko) * 2009-07-28 2011-01-14 한국생명공학연구원 대장암 과발현 유전자를 이용한 대장암 진단 마커

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007037421A (ja) * 2005-08-01 2007-02-15 Osaka Univ 大腸癌リンパ節転移の有無を予測するための遺伝子セット
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORE GOAL OF CANCER TREATMENT: CONTROL OF CHOLESTEROL METABOLISM (I, 5 September 2010 (2010-09-05), pages 1 - 6, Retrieved from the Internet <URL:http://www.herbalzym.com/ko/2010/09/%EC%95%94%EC%B9%98%EB%A3%8C%EC%9D%98-%ED%95%B5%EC%8B%AC%EB%AA%A9%ED%91%9C-%EC%BD%9C%EB%A0%88%EC%8A%A4%ED%85%8C%EB%Al%A4cholesterol-%EB%8C%80%EC%82%AC%EC%9D%98-%EC%A1%B0%EC%A0%88-1> *
HUH, JUNG WOOK ET AL.: "Clinical Significance of p53 and Ki-67 Expression in Colorectal Cancer", J. KOREAN SOC. COLOPROCTOL., vol. 25, no. 2, 2009, pages 107 - 112, XP055538749 *
KIM, JAE-O ET AL.: "Differential Expressions of Genes in Colorectal Cancer with Liver Metastasis by Using a cDNA Microarray Chip: a Pilot Study", JOURNAL OF THE KOREAN SOCIETY OF COLOPROCTOLOGY, vol. 23, no. 2, 2007, pages 116 - 128, XP055538752 *

Also Published As

Publication number Publication date
KR102006999B1 (ko) 2019-08-02
KR20180052109A (ko) 2018-05-17
WO2018088826A2 (ko) 2018-05-17

Similar Documents

Publication Publication Date Title
GB2556004A (en) Markers of stroke and stroke severity
PH12016502017A1 (en) Methods, kits and apparatus for expanding a population of cells
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
MX2020010147A (es) Metodos para predecir el riesgo de neumonia intersticial.
EP3654036A3 (en) Stomach cancer biomarker and detection method
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
MA40325A (fr) Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie.
EP3636769A4 (en) TEST KIT FOR SAMPLE NUCLEIC ACID MEASUREMENT, REAGENT AND USE OF IT
NZ629555A (en) Monocyte biomarkers for cancer detection
EP3165923A4 (en) Marker, immunoassay method, immunoassay reagent, method for assaying analyte, kit for assaying analyte, and test strip for lateral flow chromatography
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
EP3693742A3 (en) Methods of detecting prostate cancer
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
HK1251649A1 (zh) 用於測定抗體或配體結合和功能的基於細胞的測定
WO2014151290A3 (en) Assay for predictive biomarkers
MX2019000592A (es) Dispositivo dispensador de reactivos analiticos liquidos, y kits analiticos y metodos de uso relacionados.
WO2018187385A8 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING PANCREATIC CANCER
WO2018088826A3 (ko) 대장암 전이 진단 또는 예후 예측용 조성물 및 이의 용도
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.
WO2015085164A3 (en) Uveal melanoma prognosis
CN106461665A8 (zh) 用于诊断胰腺癌的包括用于特异性结合至补体因子b蛋白的抗体和用于特异性结合至糖类抗原19‑9蛋白的抗体的试剂盒

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17868855

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17868855

Country of ref document: EP

Kind code of ref document: A2